Stay updated with breaking news from Gracell Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The cash deal, which adds several experimental therapies to AstraZeneca's portfolio, values Gracell at $2 per ordinary share, or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.
DUBLIN--(BUSINESS WIRE)--The "CAR T - Cell Therapy - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 250+ companies and 500+ drugs in CAR T - Cell Therapy Competitive landscape. It covers the therapeutics assessment by product...
/PRNewswire/ -- The "China Cell Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. China...
/PRNewswire/ -- The "China Cell Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. China...
DUBLIN--(BUSINESS WIRE)--The "China Cell Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.China has emerged as one of the world's largest pharmaceutical markets as a result of a exponential rise in clinical research and development activity in rece...